{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"Grade 1-2 constipation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Grade 1-2 diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Grade 1-2 fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Grade 1-2 myalgia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Grade 1-2 nausea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Grade 1-2 neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Grade 1-2 thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Grade 3 pneumonia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Grade 3 H1N1 influenza"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Grade 3 fever, hypoxia and neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Grade 3 myalgia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Grade 3 neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44"}]}],"title":"Grade 3 neutropenia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Grade 1-2 adverse events occurring in \\>10% of participants. Grade 3 or higher adverse events occurring in one or more participants.","groups":[{"description":"Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity.\n\nlenalidomide: Given PO","id":"OG000","title":"Treatment (Lenalidomide)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 30 days after completion of study treatment","title":"Adverse Events, Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0","type":"SECONDARY","unitOfMeasure":"percentage of participants"}